The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk

Neil Caporaso, Linda Williams Pickle, Sherri Bale, Riad Ayesh, Martin Hetzel, Jeffrey Idle

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Debrisoquine hydroxylation exhibits wide inter‐individual variation in Caucasian populations. After similar doses of the drug, extensive metabolizers excrete up to several hundred times more of the urinary metabolite 4‐hydroxy‐debrisoquine than do poor metabolizers. The phenotypes have traditionally been defined by the metabolic ratio (MR), or the molar ratio of debrisoquine to its chief metabolite recovered in an aliquot of an eight hour urine sample, after a test dose of the drug. Deficient metabolism is inherited as an autosomal recessive condition. We have reanalyzed previously published data from a study of lung cancer patients and controls using a computerized optimization method to more accurately estimate the parameters describing the three phenotypic distributions. Using these new distributions to categorize controls, we show that Hardy‐Weinberg conditions are now fulfilled. When the newly defined phenotype parameters are employed to assign the phenotypes of cases and controls, a highly significant difference in phenotype distribution between cases and controls is still observed. This result supports the hypothesis that the debrisoquine metabolic phenotype may be associated with lung cancer susceptibility.

Original languageEnglish (US)
Pages (from-to)517-524
Number of pages8
JournalGenetic Epidemiology
Volume6
Issue number4
DOIs
StatePublished - Jan 1 1989

Fingerprint

Debrisoquin
Lung Neoplasms
Phenotype
Hydroxylation
Pharmaceutical Preparations
Urine
Population

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Genetics(clinical)

Cite this

Caporaso, Neil ; Pickle, Linda Williams ; Bale, Sherri ; Ayesh, Riad ; Hetzel, Martin ; Idle, Jeffrey. / The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk. In: Genetic Epidemiology. 1989 ; Vol. 6, No. 4. pp. 517-524.
@article{3e0931354ee64ae8a2d2e03307cddac7,
title = "The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk",
abstract = "Debrisoquine hydroxylation exhibits wide inter‐individual variation in Caucasian populations. After similar doses of the drug, extensive metabolizers excrete up to several hundred times more of the urinary metabolite 4‐hydroxy‐debrisoquine than do poor metabolizers. The phenotypes have traditionally been defined by the metabolic ratio (MR), or the molar ratio of debrisoquine to its chief metabolite recovered in an aliquot of an eight hour urine sample, after a test dose of the drug. Deficient metabolism is inherited as an autosomal recessive condition. We have reanalyzed previously published data from a study of lung cancer patients and controls using a computerized optimization method to more accurately estimate the parameters describing the three phenotypic distributions. Using these new distributions to categorize controls, we show that Hardy‐Weinberg conditions are now fulfilled. When the newly defined phenotype parameters are employed to assign the phenotypes of cases and controls, a highly significant difference in phenotype distribution between cases and controls is still observed. This result supports the hypothesis that the debrisoquine metabolic phenotype may be associated with lung cancer susceptibility.",
author = "Neil Caporaso and Pickle, {Linda Williams} and Sherri Bale and Riad Ayesh and Martin Hetzel and Jeffrey Idle",
year = "1989",
month = "1",
day = "1",
doi = "10.1002/gepi.1370060406",
language = "English (US)",
volume = "6",
pages = "517--524",
journal = "Genetic Epidemiology",
issn = "0741-0395",
publisher = "Wiley-Liss Inc.",
number = "4",

}

The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk. / Caporaso, Neil; Pickle, Linda Williams; Bale, Sherri; Ayesh, Riad; Hetzel, Martin; Idle, Jeffrey.

In: Genetic Epidemiology, Vol. 6, No. 4, 01.01.1989, p. 517-524.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk

AU - Caporaso, Neil

AU - Pickle, Linda Williams

AU - Bale, Sherri

AU - Ayesh, Riad

AU - Hetzel, Martin

AU - Idle, Jeffrey

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Debrisoquine hydroxylation exhibits wide inter‐individual variation in Caucasian populations. After similar doses of the drug, extensive metabolizers excrete up to several hundred times more of the urinary metabolite 4‐hydroxy‐debrisoquine than do poor metabolizers. The phenotypes have traditionally been defined by the metabolic ratio (MR), or the molar ratio of debrisoquine to its chief metabolite recovered in an aliquot of an eight hour urine sample, after a test dose of the drug. Deficient metabolism is inherited as an autosomal recessive condition. We have reanalyzed previously published data from a study of lung cancer patients and controls using a computerized optimization method to more accurately estimate the parameters describing the three phenotypic distributions. Using these new distributions to categorize controls, we show that Hardy‐Weinberg conditions are now fulfilled. When the newly defined phenotype parameters are employed to assign the phenotypes of cases and controls, a highly significant difference in phenotype distribution between cases and controls is still observed. This result supports the hypothesis that the debrisoquine metabolic phenotype may be associated with lung cancer susceptibility.

AB - Debrisoquine hydroxylation exhibits wide inter‐individual variation in Caucasian populations. After similar doses of the drug, extensive metabolizers excrete up to several hundred times more of the urinary metabolite 4‐hydroxy‐debrisoquine than do poor metabolizers. The phenotypes have traditionally been defined by the metabolic ratio (MR), or the molar ratio of debrisoquine to its chief metabolite recovered in an aliquot of an eight hour urine sample, after a test dose of the drug. Deficient metabolism is inherited as an autosomal recessive condition. We have reanalyzed previously published data from a study of lung cancer patients and controls using a computerized optimization method to more accurately estimate the parameters describing the three phenotypic distributions. Using these new distributions to categorize controls, we show that Hardy‐Weinberg conditions are now fulfilled. When the newly defined phenotype parameters are employed to assign the phenotypes of cases and controls, a highly significant difference in phenotype distribution between cases and controls is still observed. This result supports the hypothesis that the debrisoquine metabolic phenotype may be associated with lung cancer susceptibility.

UR - http://www.scopus.com/inward/record.url?scp=0024387056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024387056&partnerID=8YFLogxK

U2 - 10.1002/gepi.1370060406

DO - 10.1002/gepi.1370060406

M3 - Article

C2 - 2777072

AN - SCOPUS:0024387056

VL - 6

SP - 517

EP - 524

JO - Genetic Epidemiology

JF - Genetic Epidemiology

SN - 0741-0395

IS - 4

ER -